SUBSCRIBE
SUBSCRIBE
News   Drug Development

Hatchtech to Go to Phase II Trial

January 21, 2008 | 
1 min read
Biotechnology company Hatchtech says its new head lice treatment product will progress to phase two trials after it received the green light from the US Food and Drug Administration (FDA).
Clinical research Phase 2 Australia
MORE ON THIS TOPIC
Insights
Muscle Preservation, Tolerability and Alternative Administration Routes Define Obesity’s Drug Future
February 19, 2026
 · 
2 min read
 · 
Jennifer Smith-Parker
Silver Spring, MD, USA - June 25, 2022: The FDA White Oak Campus, headquarters of the United States Food and Drug Administration, a federal agency of the Department of Health and Human Services (HHS).
FDA
FDA Reverses Course on Moderna’s mRNA Flu Shot Application, Promising August Decision
February 18, 2026
 · 
3 min read
 · 
Heather McKenzie
Podcast
Modernagate Fallout, Disc’s Rejection, Compass’ Psilocybin Data, CDC’s Lost Leaders
February 18, 2026
 · 
1 min read
 · 
Heather McKenzie
illustration of doubtful man thinks whether to jump to the other side of the mountain, dilemma concept
Rare disease
Disc’s Regulatory Comeback Plan for Rejected Drug Relies on Old FDA Leadership
February 17, 2026
 · 
3 min read
 · 
Annalee Armstrong